Janus Kinase Inhibitors for Severe Alopecia Areata: A Systematic Literature Review and Network Meta-Analysis.
Higher-dose upadacitinib shows the strongest promise for substantial hair regrowth in severe alopecia areata within six months.
The synthesis indirectly compared oral Janus kinase inhibitors for severe alopecia areata. Upadacitinib 30 mg had the highest estimated probability of substantial hair regrowth at week 24, followed by lower-dose upadacitinib and other JAK inhibitors.
What the study was
- Study design
- Systematic review and Bayesian network meta-analysis of randomized trials
- Population
- 3739 patients with severe alopecia areata across seven phase III or IV trials
- Sample size
- 3739
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- The Journal of investigative dermatology
Why it surfaced
The network meta-analysis synthesizes phase III and IV randomized evidence, but conclusions rely on indirect comparisons
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.